Chemoembolization with Lobaplatin Mixed with Iodized Oil for Unresectable Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation

Journal of Vascular and Interventional Radiology

Volumn 21, Issue 3, 2010, Pages 333-338

  Zhou, Bin ^a   Shan, Hong ^a   Zhu, Kang Shun ^a   Jiang, Zai Bo ^a   Guan, Shou Hai ^a   Meng, Xiao Chun ^a   Zeng, Xian Cheng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IODINATED POPPYSEED OIL; LOBAPLATIN;

ADULT; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG METASTASIS; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT RESPONSE; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; COMBINED MODALITY THERAPY; CYCLOBUTANES; EMBOLIZATION, THERAPEUTIC; FEMALE; HEMOSTATICS; HUMANS; IODIZED OIL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 76449093046     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2009.11.006     Document Type: Article

References (25)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543
2. Regalia E., Fassati L.R., Valente U., et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 5 (1998) 29-34
3. Vivarelli M., Bellusci R., Cucchetti A., et al. Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?. Transplantation 74 (2002) 1746-1751
4. Roayaie S., Schwartz J.D., Sung M.W., et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10 (2004) 534-540
5. Island E.R., Pomposelli J., Pomfret E.A., et al. Twenty-year experience with liver transplantation for hepatocellular carcinoma. Arch Surg 140 (2005) 353-358
6. Bernal E., Montero J.L., Delgado M., et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc 38 (2006) 2495-2498
7. Söderdahl G., Bäckman L., Isoniemi H., et al. A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma. Transpl Int 19 (2006) 288-294
8. Brown D.B., Gould J.E., Gervais D.A., et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 18 (2007) 1469-1478
9. Roayaie S., Frischer J.S., Emre S.H., et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235 (2002) 533-539
10. Lubienski A. Hepatocellular carcinoma: interventional bridging to liver transplantation. Transplantation 80 (2005) S113-S119
11. Alba E., Valls C., Dominguez J., et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am J Roentgenol 190 (2008) 1341-1348
12. Otto G., Herber S., Heise M., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12 (2006) 1260-1267
13. Millonig G., Graziadei I.W., Freund M.C., et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 13 (2007) 272-279
14. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 246 (2007) 502-509
15. McKeage M.J. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs 10 (2001) 119-128
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guideline to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
17. Chan S.L., Mo F.K., Johnson P.J., et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27 (2009) 446-452
18. Schwartz M., Roayaie S., and Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?. Liver Transpl 43 (2005) 584-589
19. Shiina S. Image-guided percutaneous ablation therapies for hepatocellular carcinoma. J Gastroenterol 44 Suppl 19 (2009) 122-131
20. Orlando A., Leandro G., Olivo M., et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104 (2009) 514-524
21. Stuart K. Chemoembolization in the management of liver tumors. Oncologist 8 (2003) 425-437
22. Ko H.K., Ko G.Y., Yoon H.K., and Sung K.B. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol 8 (2007) 320-327
23. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 (2003) 429-442
24. Bruix J., Sala M., and Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 127 (2004) S179-S188
25. Ebied O.M., Federle M.P., Carr B.I., et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 97 (2003) 1042-1050